ReviewPharmacoEconomics2001
Accounting for noncompliance in pharmacoeconomic evaluations.
Review in PharmacoEconomics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review.Drug safety · 2012Pooled it
- Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial.BMC neurology · 2007Trial
- Measuring therapy adherence in Parkinson's disease: a comparison of methods.Journal of neurology, neurosurgery, and psychiatry · 2006Trial
- A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.Healthcare (Basel, Switzerland) · 2025Article
- Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation.Journal of personalized medicine · 2021Article
- High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.Orphanet journal of rare diseases · 2016Article
- Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.PharmacoEconomics · 2016Review
- Medication adherence in patients with Parkinson's disease.CNS drugs · 2015Review
- Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.Applied health economics and health policy · 2013Article
- Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia.Patient preference and adherence · 2013Article
- [The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].Der Nervenarzt · 2010Article
- Pharmacoeconomics and aging.Drugs & aging · 2009Review
- [Treatment adherence and persistence: causes, consequences and improvement strategies].Atencion primaria · 2009Article
- The NICE ADHD health technology assessment: a review and critique.Child and adolescent psychiatry and mental health · 2008Article
- Pharmacoeconomic impact of non-compliance with statins.PharmacoEconomics · 2005Review
- Pharmacoeconomic burden of undertreating hypertension.PharmacoEconomics · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Noncompliance with prescribed drug regimens is a widespread phenomenon which results in decreased efficacy and is often associated with increased medical expenditures. Despite this, economic evaluations based on decision-analytic models rarely incorporate noncompliance to allow for the differences in compliance observed between controlled clinical trials and routine clinical practice. This review examines the issues relating to the measurement of noncompliance, and the clinical and economic consequences of noncompliant drug taking behaviour. In order to fully appreciate the clinical (and therefore the economic) consequences of noncompliance, a detailed understanding of the type of noncompliance, the pharmacokinetic and pharmacodynamic properties of the drug and the pathophysiological processes of the diseases being treated is required. These are described in detail, and a classification of drug-disease combinations according to the potential economic impact of the varying forms of noncompliance is set out. Issues are raised to highlight the need for improved modelling of the impact of noncompliance, and to this end, recommendations are made for future analyses. The main points are that compliance should be defined clearly, distinguishing between the various forms of noncompliance, that the assumptions relating to the health status of noncompliers should be explicit and robust, and that sensitivity analysis should be applied appropriately to ascertain the impact of noncompliance on the cost-effectiveness of drug therapies.
Indexed as
Identifiers
11772154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.